Challenge
A pharmaceutical company sought to drive awareness and adoption of an oral chemotherapy drug specifically designed for 3rd/4th line treatment of metastatic colorectal (mCRC), gastric, or GEJ cancers. The primary objective was to quantify the incremental lift in prescribing behavior among healthcare professionals (HCPs) who were exposed to the EHR campaign.